Economic burden of ventilator-associated pneumonia in a developing country

The Journal of Hospital Infection
Emine AlpMehmet Doganay

Abstract

Ventilator-associated pneumonia (VAP) developed in 96 (60%) of 159 patients with 37.2 cases per 1000 ventilation-days in a medical intensive care unit (MICU). Median time for VAP development was 5.5 days (range: 2-25). The most significant risk factors for VAP were stay in hospital before MICU and length of stay in MICU. The mean length of stay in MICU for VAP patients was 23.8 ± 19.8 days, which was four-fold higher than for non-VAP patients. The daily cost for VAP patients was half that for non-VAP patients. The total costs for VAP patients were about three-fold higher than for non-VAP patients.

References

Sep 12, 1998·Annals of Internal Medicine·D J CookC Brun-Buisson
Oct 18, 2006·Annals of Internal Medicine·Victor D RosenthalUNKNOWN International Nosocomial Infection Control Consortium
Sep 8, 2010·European Journal of Internal Medicine·Noyal Mariya JosephSubhash Chandra Parija
Apr 19, 2011·Pediatrics International : Official Journal of the Japan Pediatric Society·Chun DengChunbao Guo

❮ Previous
Next ❯

Citations

Aug 16, 2016·Infectious Disease Clinics of North America·Ana Cecilia BardossyMarcus Zervos
Jul 10, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ana BonellBehzad Nadjm
Dec 1, 2018·Dimensions of Critical Care Nursing : DCCN·Mahmoud A Alja'afrehSakhaa S Habashneh
Aug 23, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Vu Quoc DatBehzad Nadjm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.